Interleukin-1 receptor type 2 (IL1R2, CD121b) is a high-affinity decoy receptor in the interleukin-1 axis. Unlike IL1R1, IL1R2 binds IL-1 ligands but does not propagate canonical pro-inflammatory signaling, so it functions as an endogenous brake on excessive cytokine activity.
IL1R2 is relevant to neurodegeneration because interleukin-1 beta (IL-1β) is consistently implicated in Alzheimer's disease, Parkinson's disease, and related neuroinflammatory states.[1][2] Current evidence supports IL1R2 primarily as a modulator of inflammatory tone rather than a standalone disease-causal protein in CNS degeneration.[1:1][3]
| Protein Name | Interleukin-1 Receptor Type 2 |
| Aliases | IL-1R2, IL-1RT2, CD121b |
| Gene | IL1R2 |
| UniProt ID | P27930 |
| Protein Class | Type I cytokine receptor, decoy receptor |
| Localization | Cell membrane and soluble extracellular form |
| Primary Function | Negative regulation of IL-1 signaling |
| Major Context | Innate immunity, neuroinflammation buffering |
IL1R2 is structurally related to signaling IL-1 receptors but differs in its intracellular region:
This architecture is the mechanistic basis for the classic “decoy receptor” model first established in foundational IL1R2 work.[4:2][5:2]
IL1R2 biology operates through two complementary forms:
Because both forms reduce effective IL-1 signaling, IL1R2 is often interpreted as part of the endogenous anti-inflammatory counter-regulatory network.
In simplified mechanistic terms:
This balance model is directly relevant to chronic neurodegenerative settings where low-grade inflammation persists for years.[2:4][7:2]
The IL-1 pathway is repeatedly linked to amyloid-associated neuroinflammation, glial activation, and synaptic dysfunction in AD literature.[2:5][7:3] IL1R2 is not a dominant AD causal gene, but it is biologically plausible as a buffering node that can dampen IL-1 burden when induced.[1:7][3:1]
Clinical and translational studies of circulating IL-1 family proteins in AD support altered cytokine-receptor homeostasis, including decoy receptor behavior, although effect sizes and cohort reproducibility vary.[8]
In PD, inflammatory activation of microglia and cytokine-network dysregulation are established contributors to neuronal stress.[2:6][9] IL1R2 is best interpreted as a candidate modulator in this environment rather than a validated monogenic PD driver. Mechanistically, higher effective IL1R2 activity could reduce IL-1-mediated amplification loops in vulnerable circuits (for example, nigrostriatal systems), but direct interventional proof remains limited.[1:8][9:1]
Across tauopathies and synucleinopathies, the translational value of IL1R2 lies in pathway control:
Evidence is strongest at pathway level and weaker for IL1R2-specific disease attribution.[1:9][2:7][3:2]
sIL1R2 is measurable in plasma/serum and may reflect anti-inflammatory counter-regulation.[6:2][8:1] In neurodegenerative cohorts, sIL1R2 should generally be interpreted alongside other inflammatory markers (for example IL-1β, IL-6, TNF family markers) rather than in isolation.[2:8][8:2]
Potential translational approaches include:
Recent reviews describe IL1R2 as an attractive anti-inflammatory target class, but clinical-neurology evidence remains early and non-definitive.[3:3]
IL1R2 contains several distinct structural domains [1]:
The ECD adopts the immunoglobulin-like fold common to the IL-1 receptor family. Ligand binding occurs in the pocket formed between Ig-like domains 2 and 3, with critical contributions from the FG loop region.
IL1R2 operates through multiple complex formation mechanisms:
| Complex | Function |
|---|---|
| IL1R2:IL-1β | Ligand sequestration |
| IL1R2:IL1R1 | Heterodimer inhibiting signaling |
| IL1R2:IL1RAP | Formation of non-signaling complexes |
| sIL1R2:IL-1β | Soluble ligand neutralization |
Quantitative binding studies reveal:
IL1R2 is expressed across multiple immune cell types:
In the central nervous system:
Key regulatory signals:
| Cytokine | Effect on IL1R2 |
|---|---|
| IL-4 | Strong induction |
| IL-13 | Strong induction |
| Glucocorticoids | Induction |
| IL-1β | Auto-regulation |
| TNF-α | Modest induction |
Key differences between IL1R2 and IL1R1:
| Feature | IL1R2 | IL1R1 |
|---|---|---|
| Signaling | None | Full NF-κB, MAPK |
| Expression | Inducible | Constitutive |
| Ligand affinity | Very high | High |
| Soluble form | Yes | Limited |
| Therapeutic target | Yes | Yes |
Other decoy receptors in the IL-1 family:
IL1R2 is the prototype and most studied decoy receptor in this family.
Therapeutic targeting strategies include:
Current clinical development:
Clinical biomarker potential:
sIL1R2 in plasma/CSF as anti-inflammatory marker: Elevated levels indicate active counter-regulation
Ratio of IL-1β/IL1R2 as inflammatory set-point: Higher ratios suggest inadequate buffering
Serial measurements for treatment monitoring: Decreasing IL-1β/IL1R2 ratio indicates response
Combination with other cytokines: Panels improve diagnostic accuracy
sIL1R2 in plasma/CSF as anti-inflammatory marker
Ratio of IL-1β/IL1R2 as inflammatory set-point
Serial measurements for treatment monitoring
Garlanda C, Dinarello CA, Mantovani A. The interleukin-1 family: back to the future. Frontiers in Immunology. 2018. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Shaftel SS, Griffin WST, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease. Journal of Neuroinflammation. 2008. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Ji Y, Wei J, Wang Y, et al. Interleukin-1 receptor type 2 as potential therapeutic target in inflammatory diseases. Frontiers in Immunology. 2024. ↩︎ ↩︎ ↩︎ ↩︎
Colotta F, Re F, Muzio M, et al. Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4. Science. 1993. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Mantovani A, Locati M, Vecchi A, et al. Decoy receptors: a strategy to regulate inflammatory cytokines and chemokines. Trends in Immunology. 1995. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Cui X, Rouhani FN, Hawari F, Levine SJ. An interleukin-1 receptor type II exon 9 deletion mutant is a dominant negative receptor. Journal of Biological Chemistry. 2003. ↩︎ ↩︎ ↩︎
Griffin WST, Stanley LC, Ling C, et al. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proceedings of the National Academy of Sciences USA. 1989. ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Licastro F, Pedrini S, Caputo L, et al. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. Journal of Neuroimmunology. 2000. ↩︎ ↩︎ ↩︎ ↩︎
Hirsch EC, Vyas S, Hunot S. Neuroinflammation in Parkinson's disease. Parkinsonism & Related Disorders. 2012. ↩︎ ↩︎ ↩︎